DROPLETS

The Patient AI Act, introduced in Congress, would establish a new federal framework for AI‑enabled health technologies. By clarifying how the FDA evaluates such devices and streamlining post‑market review, the bill could accelerate approvals for innovative AI‑driven diagnostics and therapeutics. Crucially, it addresses unmet reimbursement challenges by leveraging existing Medicare and Medicaid payment models to explicitly cover AI‑based treatments and diagnostics. For major‑firm clients, the Act signals a potential federal reimbursement path that could reduce reliance on costly, fragmented state and payer processes. In addition, the framework would create guidelines for data governance, clinical validation, and transparency, aiding regulators and manufacturers in meeting regulatory and commercial thresholds. Legal teams should monitor the bill’s progression, assess compliance impacts for forthcoming AI products, and prepare stakeholder briefings to align their clients’ development strategies with the evolving regulatory environment.

In a narrow 4‑to‑1 vote, the Ninth Circuit issued a preliminary injunction against enforcement of California Senate Bill 261, the state’s climate‑related disclosure requirement that obliges regulated entities to report greenhouse‑gas emissions, carbon‑intensity metrics, and climate‑risk strategies. The court cited potential irreparable harm to businesses and lack of evidence that the statutory framework adequately balanced First Amendment and due‑process concerns. The injunction does not alter the statute itself, but it pauses its implementation pending further litigation, leaving California firms uncertain about future compliance deadlines.

…

New Jersey’s 2026 regulation expands state guidance on independent contractor classification by adopting the ABC test—an approach that requires employers to prove that services are performed outside the usual duties and that the worker operates independently. The rule goes into effect on Oct. 1 and applies to all service-based arrangements, from on‑site tech support to freelance marketing. Firms with clients across New Jersey, especially those with large gig or remote workforces, will need to reassess their classification spreadsheets and potentially reclassify staff to avoid employment misclassification penalties. Key compliance steps include reviewing engagement agreements, updating payroll systems, and training managers to apply the ABC criteria. As an interim measure, employers may file for a determination letter from the NJ Department of Labor to clarify ambiguous cases. Given the potential for increased whistleblower liability and unionization pressure, the rule represents a substantial shift in workforce strategy for New Jersey‑based businesses.

The ministerial statement delivered on 4 November 2026 signals that the UK will enact a mandatory human‑rights due‑diligence (mHRDD) regime, requiring companies to identify and mitigate human‑rights risks in their supply chains, activities, and investments. The new rule builds on voluntary guidelines that have been in place for years, and could compel firms—from multinationals to SMEs—to conduct formal assessments, report findings, and take remedial actions. The change aligns with the UK’s commitments under the UK‑Human‑Rights Act and reflects a broader trend toward regulatory enforcement of corporate responsibility in human rights. Legal teams will need to assess the scope of compliance, prepare robust due‑diligence frameworks, and monitor for updates on statutory thresholds and reporting obligations. Clients should anticipate potential audit and litigation exposure if they fail to meet the mandated standards, and should begin aligning internal policies to the impending requirement. This development is cross‑client and cross‑firm, as nearly every sector will be impacted, making it

…

On October 21, 2026, the Office of the Comptroller of the Currency issued a definitive final rule implementing the Guiding and Establishing National Innovation for U.S. Stablecoins Act (GENIUS Act). The rule obligates any stablecoin issuer falling under OCC jurisdiction to obtain a banking or trust charter and to meet the prudential, anti‑money‑laundering, and disclosure standards now codified in the new framework. For issuers, this means a new track that parallels both traditional banking supervision and the SEC’s securities oversight, requiring detailed financial reporting, capital buffers, and regulatory reporting schedules. The rule also clarifies the OCC’s jurisdictional boundaries, including leverage and derivative usage, and sets out supervisory visit expectations. Entities that previously operated as issuers without a bank license must decide whether to apply for a charter, partner with an OCC‑chartered bank, or explore alternative structures. The timing of the rule is timely as the stablecoin market is poised for rapid growth; firms should review asset‑type classificati

…

The Ninth Circuit’s latest opinion splintered the arguments it could decide. While the court found that certain disclosure provisions of California’s Climate Corporate Data Accountability Act (SB 253) and Climate‑Related Financial Risk Act (SB 261) do not violate the First Amendment, it left open several substantive questions about the state’s ability to demand comprehensive environmental data from private firms. The decision underscores the limits of state climate‑policy disclosures that may be viewed as compelled speech. For multi‑national and U.S.‑based clients, the ruling signals that, while some disclosures remain permissible, other clauses—especially those requiring attribution to actual greenhouse‑gas emitters—may be challenged. Firms should re‑examine their climate‑reporting frameworks to identify which questions are safe under the current Ninth Circuit framework and which might need revision.

On Nov. 5, 2026, CMS issued a final rule codifying the Inflation Reduction Act’s Drug Price Negotiation Program (DPNP), the first statutory framework that allows Medicare to negotiate prices for certain high‑cost drugs. The rule sets eligibility criteria, establishes negotiation timelines, and defines price‑reduction caps and enforcement mechanisms. It also requires manufacturers to provide cost‑effectiveness data and establishes a dedicated CMS Office of Drug Pricing Studies to monitor outcomes. The program will begin negotiating starting in 2029, impacting all drugs listed above the threshold. This change introduces a new compliance dimension for pharma clients and could materially shift market pricing strategies. Firms should review the eligibility test, negotiate timelines, and adjust pricing models and contracts accordingly. Surveillance of the program’s implementation will be critical, as CMS may refine the rule based on market feedback.

The USTR’s latest update extends the Section 301 maritime fee and the suspension of duties on ship‑to‑shore (STS) cranes and related cargo‑handling equipment for goods shipped from China. Effective as of this week, the fee – a $200 per service visit surcharge for maritime transport operators – remains in place until January 9, 2027, while the duty on STS cranes continues to be waived under the existing Section 301 tariff framework. The move is part of the U.S. government’s broader effort to counter potential national‑security concerns linked to Chinese shipping infrastructure. Practical effects include additional cost layers for U.S. freight forwarders, port operators and shipping lines that use STS equipment to move cargo on Chinese vessels. Firms with significant wagon deployments in Asia-Pacific ports should review pricing models, update customs filings, and ensure compliance with the fee schedule. The suspension’s extension also signals ongoing scrutiny of Chinese maritime operations, hinting at a prolonged trade‑tension environment.

In a narrow decision dated October 16, 2026, the Fourth Circuit held that Title VII’s Section 702 religious employer exemption protects only against religious discrimination, not against sex, race or national‑origin claims—even when an employer’s motive is religious. The court applied the same reasoning to Maryland’s Fair Employment Practices Act, overturning the earlier Maryland Supreme Court’s broader shield for mission‑related work. The decision also rejected the Religious Freedom Restoration Act as a shield in private suits and limited the church‑autonomy doctrine to ministerial issues. For faith‑affiliated employers in Maryland, Virginia, North Carolina, South Carolina and West Virginia, the ruling means that benefits—such as dependent health coverage—must comply with federal and state antidiscrimination laws even if the decision was rooted in religious values. Firms advising such nonprofits should review benefit eligibility policies, document non‑ministerial duties, and ensure recruiters communicate consistent eligibility criteria. The split decision and the Ninth Circuit’s pen

…

The 2026 U.S. midterm election ushered in a Texas legislature more skeptical of new data‑center development, sparking concerns that state and local policymakers could alter permitting requirements, renegotiate utility contracts, or withdraw tax‑break incentives. Those changes would force developers to absorb higher interest costs during construction, pay for equipment on a lagging schedule, or negotiate higher utility rates—factors that can render projects economically unviable. Firms advising on data‑center construction should anticipate insurance reforms, consult local statutes on tax credit regimes, and structure phased financing to mitigate the risk of falling into “dead‑weight” cost overruns. Close monitoring of Texas legislative bills, coupled with proactive client engagement on fee‑S‑1 issuances and utility competition provisions, will be essential for clients seeking to maintain their AI‑expansion timelines while keeping projects within budget.